Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Bussel JB, et al. Among authors: david m. Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28. Lancet Haematol. 2015. PMID: 26688484 Clinical Trial.
Chronic immune thrombocytopenic purpura in children: a survey of the canadian experience.
Belletrutti M, Ali K, Barnard D, Blanchette V, Chan A, David M, Luke B, Price V, Ritchie B, Wu J; Canadian Pediatric Chronic ITP Working Group; Canadian Pediatric Thrombosis and Hemostasis Network. Belletrutti M, et al. Among authors: david m. J Pediatr Hematol Oncol. 2007 Feb;29(2):95-100. doi: 10.1097/MPH.0b013e3180320b36. J Pediatr Hematol Oncol. 2007. PMID: 17279005
Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents.
Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S, Blanchette V; Canadian Children's Platelet Study Group. Barnard D, et al. Among authors: david m. J Pediatr Hematol Oncol. 2003 Jan;25(1):56-62. doi: 10.1097/00043426-200301000-00011. J Pediatr Hematol Oncol. 2003. PMID: 12544774
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Halton J, et al. Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5. Lancet Haematol. 2021. PMID: 33290737 Clinical Trial.
Heparin therapy in pediatric patients: a prospective cohort study.
Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, Burrows P, Benson L, Williams W, David M, et al. Andrew M, et al. Among authors: david m. Pediatr Res. 1994 Jan;35(1):78-83. doi: 10.1203/00006450-199401000-00016. Pediatr Res. 1994. PMID: 8134203 Clinical Trial.
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Brandão LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M; DIVERSITY Study Investigators. Brandão LR, et al. Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998. Blood. 2020. PMID: 31805182 Free PMC article. Clinical Trial.
3,303 results